We evaluated a novel treatment for obesity-related renal, an ATP-citrate lyase (ACL) inhibitor, to attenuate ectopic lipid accumulation (ELA) in the kidney and the ensuing inflammation. This evidence concerns the gene ACLY and obesity due to melanocortin 4 receptor deficiency.